With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

2.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

3.

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.

4.

Sustained reduction found in prostate cancer mortality with prostate-specific antigen screening

5.

A paper strip test might enable the early detection of cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot